Recently, we have reported that enhanced rates of acquired chromosomal aberrations, clonal evolution and fast disease progression (time to BC) in CML patients undergoing long-term IM treatment correlate with enhanced proteolytic activity of Separase in the respective in vitro models [35]. Here, ESPL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.